BRANFORD, Conn.–(BUSINESS WIRE)–Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the third quarter ended September 30, 2023.
Q3 and Recent Business Highlights
- Advanced its pipeline programs including ATR-12 (Netherton syndrome), ATR-04 (EGFRi-associated rash) and its Joint Development Agreement with Bayer
- Completed and filed post-IND, FDA commitments for characterization of drug product for ATR-12
- Selected and hired clinical research organization for ATR-12 clinical trial. Selected initial sites for activation
Francisco Salva, Chief Executive Officer of Azitra, commented:
“During the third quarter, we made important progress towards reaching multiple significant near-term milestones. Firstly, for our lead program ATR-12 for Netherton syndrome, we’ve selected and hired our clinical research organization for the Netherton syndrome clinical trial. Additionally, we are in discussion with our lead sites to get the program activated and start recruiting an initial ~12 patients. We’re now poised for key catalysts, including first patient enrolled, followed by initial clinical data in 2024.”
“Next, for our ATR-04 program targeting EGFRi-associated rash, we’ve been advancing towards our IND (Investigational New Drug) filing to enable clinical development. We are moving through the necessary preclinical and manufacturing activities. We are now building towards several pivotal events over the next 12 to 18 months, starting with IND submission, followed by enrolling ~15 patients, and then announcing data.”
“Additionally, regarding our Joint Development Agreement with Bayer, we are very pleased with the recent progress of our collaboration.”
Pipeline and Upcoming Milestones
-
ATR-12 – Netherton syndrome (rare skin disease with no FDA approved treatment options). Global Prevalence: 20K+ patients. Estimated Peak Sales Opportunity: ~$250 million.
- Clinical Status: Phase 1b IND cleared
-
Upcoming milestones:
- First patient enrolled (FPI)
- Initial clinical data
-
ATR-04 – EGFRi-associated rash (Chemotherapy agents such as EGFR inhibitors and immunotherapies such as early BTK inhibitors lead to an aggressive and debilitating rash on many patients). US Prevalence: 200K+ patients. Estimated Peak Sales Opportunity: >$1B.
- Clinical Status: Pre-IND
-
Upcoming milestones:
- Preclinical animal data
- IND submission
-
Bayer Joint Development Agreement (Joint development on S. epidermidis strains and products for eczema-prone skin.) Global Prevalence: 230 million. Annual economic burden in Europe: $30B.
- Status: Azitra is responsible for early research, and Bayer is responsible for clinical development and commercialization
-
Upcoming milestones:
- Execution of royalty-bearing licensing agreement
Financial Results for the Three Months Ended September 30, 2023
- Cash and cash equivalents: As of September 30, 2023, the Company had cash and cash equivalents of $4.4 million.
- Service Revenue – Related Party: The Company generated $310,700 of service revenue during the three months ended September 30, 2023 compared to $48,500 for the comparable period in 2022.
- Research and Development (R&D) expenses: R&D expenses for the three months ended September 30, 2023 were $548,524 compared to $1.4 million from the prior year period.
- General and Administrative (G&A) expenses: G&A expenses for the three months ended September 30, 2023 were $1.8 million compared to $1.1 million from the prior year period.
- Net Loss was $1.9 million for the three months ended September 30 2023, compared to $2.4 million for the same period in 2022.
About Azitra, Inc.
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the Company’s library of strains for drug like molecules. The Company’s initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit https://azitrainc.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of the presentation of data from the Phase 1b study of ATR-12, the filing of an IND application, and the presentation of data from our Phase 1b for ATR-04, the IND filing for ATR-01, the timing of having a signed license agreement with Bayer, and statements about our clinical and pre-clinical programs, and corporate and clinical/pre-clinical strategies.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to successfully complete our Phase 1b trial for ATR-12 and pre-clinical studies of other product candidates and obtain required approval before commercialization; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra’s programs and operations are described in its registration statement on Form S-1, which is on file with the SEC, and in its most recent quarterly report on Form 10-Q to be filed with the SEC. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
|
Condensed Consolidated Statement of Operations (Unaudited)
|
||||||||
|
|
Three months Ended September 30, |
|||||||
|
|
2023 |
|
2022 |
|
||||
|
Service revenue – related party |
$ |
310,700 |
|
$ |
48,500 |
|
||
|
Total revenue |
|
310,700 |
|
|
48,500 |
|
||
|
|
|
|
|
|
||||
|
Operating expenses: |
|
|
|
|
||||
|
General and administrative |
|
1,755,908 |
|
|
1,054,570 |
|
||
|
Research and development |
|
548,524 |
|
|
1,364,380 |
|
||
|
Total operating expenses |
|
2,304,432 |
|
|
2,418,950 |
|
||
|
|
|
|
|
|
||||
|
Loss from operations |
|
(1,993,732 |
) |
|
(2,370,450 |
) |
||
|
|
|
|
|
|
||||
|
Other income (expense): |
|
|
|
|
||||
|
Interest income |
|
634 |
|
|
3,201 |
|
||
|
Interest expense |
|
(710 |
) |
|
(31,333 |
) |
||
|
Other expense |
|
50,519 |
|
|
(19,038 |
) |
||
|
Total other income (expense) |
|
50,443 |
|
|
(47,170 |
) |
||
|
|
|
|
|
|
||||
|
Net loss before income taxes |
|
(1,943,289 |
) |
|
(2,417,620 |
) |
||
|
|
|
|
|
|
||||
|
Income tax benefit (expense) |
|
– |
|
|
– |
|||
|
|
|
|
|
|
||||
|
Net loss |
$ |
(1,943,289 |
) |
|
(2,417,620 |
) |
||
|
Dividends on preferred stock |
|
– |
|
|
(692,246 |
) |
||
|
Net loss attributable to common shareholders |
$ |
(1,943,289 |
) |
|
(3,109,866 |
) |
||
|
Net loss per Share, basic and diluted |
|
(.16 |
) |
|
(2.95 |
) |
||
|
Weighted average common stock outstanding, basic and diluted |
$ |
12,097,643 |
|
$ |
1,055,455 |
|
||
|
Condensed Consolidated Balance Sheets (Unaudited)
|
||||||||
|
|
September 30, |
December 31, |
||||||
|
|
2023 |
|
2022 |
|
||||
|
Assets |
|
|
|
|
||||
|
Current Assets: |
|
|
|
|||||
|
Cash and cash equivalents |
$ |
4,400,327 |
|
$ |
3,492,656 |
|
||
|
Other receivables |
|
54,247 |
|
|
266,208 |
|
||
|
Prepaid expenses and other current assets |
|
409,170 |
|
|
377,019 |
|
||
|
Total current assets |
$ |
4,863,744 |
|
$ |
4,135,883 |
|
||
|
Property and equipment, net |
|
736,423 |
|
|
846,958 |
|
||
|
Other assets |
|
1,890,077 |
|
|
2,184,602 |
|
||
|
Total assets |
$ |
7,490,244 |
|
$ |
7,167,443 |
|
||
|
Liabilities, preferred stock, and stockholders’ equity |
|
|
|
|
||||
|
Current liabilities: |
|
|
|
|
||||
|
Accounts payable |
$ |
417,928 |
|
$ |
784,687 |
|
||
|
Current financing lease liability |
|
14,254 |
|
|
– |
|
||
|
Current operating lease liability |
|
301,423 |
|
|
287,384 |
|
||
|
Accrued expenses |
|
720,095 |
|
|
993,961 |
|
||
|
Contract liabilities |
|
– |
|
|
156,000 |
|
||
|
Total current liabilities |
|
1,453,700 |
|
|
2,222,032 |
|
||
|
Long-term financing lease liability |
|
29,952 |
|
|
– |
|
||
|
Long-term operating lease liability |
|
613,572 |
|
|
840,896 |
|
||
|
Warrant liability |
|
60,933 |
|
|
70,283 |
|
||
|
Convertible notes payable, net |
|
0 |
|
|
6,600,000 |
|
||
|
Total liabilities |
|
2,158,157 |
|
|
9,733,211 |
|
||
|
Stockholders’ equity (deficit) |
|
|
|
|
||||
|
Preferred stock |
|
0 |
|
|
33,694,542 |
|
||
|
Common stock |
|
1,210 |
|
|
104 |
|
||
|
Additional paid-in capital |
|
51,475,425 |
|
|
1,054,138 |
|
||
|
Accumulated deficit |
|
(46,144,548 |
) |
|
(37,314,552 |
) |
||
|
Total stockholders’ equity (deficit) |
|
5,332,087 |
|
|
(36,260,310 |
) |
||
|
Total liabilities, preferred stock and stockholders’ equity (deficit) |
$ |
7,490,244 |
|
$ |
7,167,443 |
|
||
Contacts
Norman Staskey
Chief Financial Officer
staskey@azitra.com
Hayden IR
James Carbonara
(646) 755-7412
james@haydenir.com